CEO Stéphane Bancel said on Thursday that his company will not fund further late-stage development of vaccines as the U.S.

As the Trump administration erodes U.S. infrastructure supporting infectious disease vaccines, mRNA heavyweight Moderna plans ...

The comments from Moderna CEO Stéphane Bancel comments are some of his strongest yet about the difficulties that vaccine ...

Jan 22 (Reuters) - Moderna does not plan to invest in new late-stage vaccine trials because of growing opposition to ...

Moderna CEO Stéphane Bancel positions 2026 as a catalyst-rich year driven by new vaccine launches, late-stage oncology data, ...

COVID pivot at Davos, betting on personalised mRNA cancer therapies, new vaccine launches, and AI-led drug development to ...

The five-year results come from a phase 2b study that tested intismeran autogene in combination with Merck’s Keytruda in ...

Commonwealth Fusion Systems (CFS), the largest and leading private fusion company, today announced that Stephane Bancel, the Chief Executive Officer of Moderna Inc. who led that company's successful ...

US biotech Moderna today announced business updates and progress across its pipeline of mRNA medicines. Moderna enters 2026 ...

(NASDAQ:MRNA) today provided an update on regulatory submissions for its investigational seasonal influenza vaccine, mRNA-1010, for adults aged 50 years and older. The Company has filed for marketing ...

Full-year 2025 revenue guidance narrowed to $1.6 billion to $2 billion. The U.S. sales outlook is now $1 billion to $1.3 billion and international sales $600 million to $700 million. Mock explained, ...

Oct 20 (Reuters) - Moderna Inc (MRNA.O), opens new tab Chief Executive Officer Stéphane Bancel expects interim results from its COVID-19 vaccine trial in November and that the U.S government could ...